Financhill
Buy
56

LXRX Quote, Financials, Valuation and Earnings

Last price:
$1.09
Seasonality move :
-6.75%
Day range:
$1.07 - $1.19
52-week range:
$0.28 - $2.45
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
12.64x
P/B ratio:
3.34x
Volume:
5.2M
Avg. volume:
4.7M
1-year change:
-30.67%
Market cap:
$410.4M
Revenue:
$31.1M
EPS (TTM):
-$0.51

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
LXRX
Lexicon Pharmaceuticals
$4.9M -$0.08 195.54% -54.41% $2.58
ALLO
Allogene Therapeutics
-- -$0.26 -92.41% -24.29% $8.15
CAPR
Capricor Therapeutics
$1.3M -$0.46 -67.82% -30.36% $34.60
CLPT
ClearPoint Neuro
$9.2M -$0.20 17.08% -25% $29.00
INO
Inovio Pharmaceuticals
$8.3K -$0.62 -90.08% -46.85% $7.50
VXRT
Vaxart
$2M -$0.10 -68.36% -5.56% $4.67
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
LXRX
Lexicon Pharmaceuticals
$1.13 $2.58 $410.4M -- $0.00 0% 12.64x
ALLO
Allogene Therapeutics
$1.26 $8.15 $275.6M -- $0.00 0% 2,988.01x
CAPR
Capricor Therapeutics
$11.40 $34.60 $521.1M -- $0.00 0% 19.82x
CLPT
ClearPoint Neuro
$11.96 $29.00 $338M -- $0.00 0% 10.25x
INO
Inovio Pharmaceuticals
$1.39 $7.50 $51M -- $0.00 0% --
VXRT
Vaxart
$0.35 $4.67 $79.2M -- $0.00 0% 1.59x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
LXRX
Lexicon Pharmaceuticals
45.01% -0.442 60.17% 2.19x
ALLO
Allogene Therapeutics
-- -0.132 -- 12.46x
CAPR
Capricor Therapeutics
-- 2.295 -- 7.70x
CLPT
ClearPoint Neuro
-- 0.234 -- 2.34x
INO
Inovio Pharmaceuticals
-- 1.621 -- 2.55x
VXRT
Vaxart
-- 0.841 -- 0.59x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
LXRX
Lexicon Pharmaceuticals
$1.2M -$25.7M -60.04% -90.8% -1858.95% -$43.8M
ALLO
Allogene Therapeutics
-- -$65.2M -52.73% -52.73% -315927.27% -$53M
CAPR
Capricor Therapeutics
-- -$25M -75.99% -75.99% -69.16% -$7.6M
CLPT
ClearPoint Neuro
$5.1M -$6.2M -64.56% -73.69% -72.63% -$6.4M
INO
Inovio Pharmaceuticals
-- -$25.1M -125.47% -125.47% -30140.49% -$26.9M
VXRT
Vaxart
-- -$14.9M -94.14% -94.14% -69.45% -$9.7M

Lexicon Pharmaceuticals vs. Competitors

  • Which has Higher Returns LXRX or ALLO?

    Allogene Therapeutics has a net margin of -2004.36% compared to Lexicon Pharmaceuticals's net margin of -295454.55%. Lexicon Pharmaceuticals's return on equity of -90.8% beat Allogene Therapeutics's return on equity of -52.73%.

    Company Gross Margin Earnings Per Share Invested Capital
    LXRX
    Lexicon Pharmaceuticals
    97.62% -$0.07 $223.7M
    ALLO
    Allogene Therapeutics
    -- -$0.28 $461.4M
  • What do Analysts Say About LXRX or ALLO?

    Lexicon Pharmaceuticals has a consensus price target of $2.58, signalling upside risk potential of 128.32%. On the other hand Allogene Therapeutics has an analysts' consensus of $8.15 which suggests that it could grow by 546.83%. Given that Allogene Therapeutics has higher upside potential than Lexicon Pharmaceuticals, analysts believe Allogene Therapeutics is more attractive than Lexicon Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    LXRX
    Lexicon Pharmaceuticals
    1 2 0
    ALLO
    Allogene Therapeutics
    8 2 0
  • Is LXRX or ALLO More Risky?

    Lexicon Pharmaceuticals has a beta of 1.129, which suggesting that the stock is 12.928% more volatile than S&P 500. In comparison Allogene Therapeutics has a beta of 0.308, suggesting its less volatile than the S&P 500 by 69.171%.

  • Which is a Better Dividend Stock LXRX or ALLO?

    Lexicon Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Allogene Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Lexicon Pharmaceuticals pays -- of its earnings as a dividend. Allogene Therapeutics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios LXRX or ALLO?

    Lexicon Pharmaceuticals quarterly revenues are $1.3M, which are larger than Allogene Therapeutics quarterly revenues of $22K. Lexicon Pharmaceuticals's net income of -$25.3M is higher than Allogene Therapeutics's net income of -$59.7M. Notably, Lexicon Pharmaceuticals's price-to-earnings ratio is -- while Allogene Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Lexicon Pharmaceuticals is 12.64x versus 2,988.01x for Allogene Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    LXRX
    Lexicon Pharmaceuticals
    12.64x -- $1.3M -$25.3M
    ALLO
    Allogene Therapeutics
    2,988.01x -- $22K -$59.7M
  • Which has Higher Returns LXRX or CAPR?

    Capricor Therapeutics has a net margin of -2004.36% compared to Lexicon Pharmaceuticals's net margin of -63.94%. Lexicon Pharmaceuticals's return on equity of -90.8% beat Capricor Therapeutics's return on equity of -75.99%.

    Company Gross Margin Earnings Per Share Invested Capital
    LXRX
    Lexicon Pharmaceuticals
    97.62% -$0.07 $223.7M
    CAPR
    Capricor Therapeutics
    -- -$0.53 $145.5M
  • What do Analysts Say About LXRX or CAPR?

    Lexicon Pharmaceuticals has a consensus price target of $2.58, signalling upside risk potential of 128.32%. On the other hand Capricor Therapeutics has an analysts' consensus of $34.60 which suggests that it could grow by 203.51%. Given that Capricor Therapeutics has higher upside potential than Lexicon Pharmaceuticals, analysts believe Capricor Therapeutics is more attractive than Lexicon Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    LXRX
    Lexicon Pharmaceuticals
    1 2 0
    CAPR
    Capricor Therapeutics
    7 0 0
  • Is LXRX or CAPR More Risky?

    Lexicon Pharmaceuticals has a beta of 1.129, which suggesting that the stock is 12.928% more volatile than S&P 500. In comparison Capricor Therapeutics has a beta of 0.820, suggesting its less volatile than the S&P 500 by 18.02%.

  • Which is a Better Dividend Stock LXRX or CAPR?

    Lexicon Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Capricor Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Lexicon Pharmaceuticals pays -- of its earnings as a dividend. Capricor Therapeutics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios LXRX or CAPR?

    Lexicon Pharmaceuticals quarterly revenues are $1.3M, which are smaller than Capricor Therapeutics quarterly revenues of $11.1M. Lexicon Pharmaceuticals's net income of -$25.3M is lower than Capricor Therapeutics's net income of -$24.4M. Notably, Lexicon Pharmaceuticals's price-to-earnings ratio is -- while Capricor Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Lexicon Pharmaceuticals is 12.64x versus 19.82x for Capricor Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    LXRX
    Lexicon Pharmaceuticals
    12.64x -- $1.3M -$25.3M
    CAPR
    Capricor Therapeutics
    19.82x -- $11.1M -$24.4M
  • Which has Higher Returns LXRX or CLPT?

    ClearPoint Neuro has a net margin of -2004.36% compared to Lexicon Pharmaceuticals's net margin of -71.02%. Lexicon Pharmaceuticals's return on equity of -90.8% beat ClearPoint Neuro's return on equity of -73.69%.

    Company Gross Margin Earnings Per Share Invested Capital
    LXRX
    Lexicon Pharmaceuticals
    97.62% -$0.07 $223.7M
    CLPT
    ClearPoint Neuro
    60.48% -$0.22 $20M
  • What do Analysts Say About LXRX or CLPT?

    Lexicon Pharmaceuticals has a consensus price target of $2.58, signalling upside risk potential of 128.32%. On the other hand ClearPoint Neuro has an analysts' consensus of $29.00 which suggests that it could grow by 142.48%. Given that ClearPoint Neuro has higher upside potential than Lexicon Pharmaceuticals, analysts believe ClearPoint Neuro is more attractive than Lexicon Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    LXRX
    Lexicon Pharmaceuticals
    1 2 0
    CLPT
    ClearPoint Neuro
    2 0 0
  • Is LXRX or CLPT More Risky?

    Lexicon Pharmaceuticals has a beta of 1.129, which suggesting that the stock is 12.928% more volatile than S&P 500. In comparison ClearPoint Neuro has a beta of 0.917, suggesting its less volatile than the S&P 500 by 8.296%.

  • Which is a Better Dividend Stock LXRX or CLPT?

    Lexicon Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ClearPoint Neuro offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Lexicon Pharmaceuticals pays -- of its earnings as a dividend. ClearPoint Neuro pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios LXRX or CLPT?

    Lexicon Pharmaceuticals quarterly revenues are $1.3M, which are smaller than ClearPoint Neuro quarterly revenues of $8.5M. Lexicon Pharmaceuticals's net income of -$25.3M is lower than ClearPoint Neuro's net income of -$6M. Notably, Lexicon Pharmaceuticals's price-to-earnings ratio is -- while ClearPoint Neuro's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Lexicon Pharmaceuticals is 12.64x versus 10.25x for ClearPoint Neuro. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    LXRX
    Lexicon Pharmaceuticals
    12.64x -- $1.3M -$25.3M
    CLPT
    ClearPoint Neuro
    10.25x -- $8.5M -$6M
  • Which has Higher Returns LXRX or INO?

    Inovio Pharmaceuticals has a net margin of -2004.36% compared to Lexicon Pharmaceuticals's net margin of -30140.49%. Lexicon Pharmaceuticals's return on equity of -90.8% beat Inovio Pharmaceuticals's return on equity of -125.47%.

    Company Gross Margin Earnings Per Share Invested Capital
    LXRX
    Lexicon Pharmaceuticals
    97.62% -$0.07 $223.7M
    INO
    Inovio Pharmaceuticals
    -- -$0.51 $51.3M
  • What do Analysts Say About LXRX or INO?

    Lexicon Pharmaceuticals has a consensus price target of $2.58, signalling upside risk potential of 128.32%. On the other hand Inovio Pharmaceuticals has an analysts' consensus of $7.50 which suggests that it could grow by 439.57%. Given that Inovio Pharmaceuticals has higher upside potential than Lexicon Pharmaceuticals, analysts believe Inovio Pharmaceuticals is more attractive than Lexicon Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    LXRX
    Lexicon Pharmaceuticals
    1 2 0
    INO
    Inovio Pharmaceuticals
    2 2 0
  • Is LXRX or INO More Risky?

    Lexicon Pharmaceuticals has a beta of 1.129, which suggesting that the stock is 12.928% more volatile than S&P 500. In comparison Inovio Pharmaceuticals has a beta of 1.307, suggesting its more volatile than the S&P 500 by 30.734%.

  • Which is a Better Dividend Stock LXRX or INO?

    Lexicon Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Inovio Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Lexicon Pharmaceuticals pays -- of its earnings as a dividend. Inovio Pharmaceuticals pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios LXRX or INO?

    Lexicon Pharmaceuticals quarterly revenues are $1.3M, which are larger than Inovio Pharmaceuticals quarterly revenues of $65.3K. Lexicon Pharmaceuticals's net income of -$25.3M is lower than Inovio Pharmaceuticals's net income of -$19.7M. Notably, Lexicon Pharmaceuticals's price-to-earnings ratio is -- while Inovio Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Lexicon Pharmaceuticals is 12.64x versus -- for Inovio Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    LXRX
    Lexicon Pharmaceuticals
    12.64x -- $1.3M -$25.3M
    INO
    Inovio Pharmaceuticals
    -- -- $65.3K -$19.7M
  • Which has Higher Returns LXRX or VXRT?

    Vaxart has a net margin of -2004.36% compared to Lexicon Pharmaceuticals's net margin of -74.68%. Lexicon Pharmaceuticals's return on equity of -90.8% beat Vaxart's return on equity of -94.14%.

    Company Gross Margin Earnings Per Share Invested Capital
    LXRX
    Lexicon Pharmaceuticals
    97.62% -$0.07 $223.7M
    VXRT
    Vaxart
    -- -$0.07 $45.6M
  • What do Analysts Say About LXRX or VXRT?

    Lexicon Pharmaceuticals has a consensus price target of $2.58, signalling upside risk potential of 128.32%. On the other hand Vaxart has an analysts' consensus of $4.67 which suggests that it could grow by 1244.86%. Given that Vaxart has higher upside potential than Lexicon Pharmaceuticals, analysts believe Vaxart is more attractive than Lexicon Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    LXRX
    Lexicon Pharmaceuticals
    1 2 0
    VXRT
    Vaxart
    3 0 0
  • Is LXRX or VXRT More Risky?

    Lexicon Pharmaceuticals has a beta of 1.129, which suggesting that the stock is 12.928% more volatile than S&P 500. In comparison Vaxart has a beta of 1.144, suggesting its more volatile than the S&P 500 by 14.422%.

  • Which is a Better Dividend Stock LXRX or VXRT?

    Lexicon Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vaxart offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Lexicon Pharmaceuticals pays -- of its earnings as a dividend. Vaxart pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios LXRX or VXRT?

    Lexicon Pharmaceuticals quarterly revenues are $1.3M, which are smaller than Vaxart quarterly revenues of $20.9M. Lexicon Pharmaceuticals's net income of -$25.3M is lower than Vaxart's net income of -$15.6M. Notably, Lexicon Pharmaceuticals's price-to-earnings ratio is -- while Vaxart's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Lexicon Pharmaceuticals is 12.64x versus 1.59x for Vaxart. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    LXRX
    Lexicon Pharmaceuticals
    12.64x -- $1.3M -$25.3M
    VXRT
    Vaxart
    1.59x -- $20.9M -$15.6M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

What Is the Ceiling for IONQ Stock?
What Is the Ceiling for IONQ Stock?

IonQ (NYSE:IONQ) is a quantum computing startup that, like many…

Can FUBO Stock Double?
Can FUBO Stock Double?

TV streaming service Fubo (NYSE:FUBO) has seen incredible returns so…

Where Will CoreWeave Stock Be in 1 Year?
Where Will CoreWeave Stock Be in 1 Year?

When CoreWeave (NASDAQ: CRWV) slipped below its $40 IPO price…

Stock Ideas

Buy
69
Is NVDA Stock a Buy?

Market Cap: $4T
P/E Ratio: 56x

Buy
53
Is MSFT Stock a Buy?

Market Cap: $3.7T
P/E Ratio: 42x

Sell
46
Is AAPL Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 35x

Alerts

Buy
76
MP alert for Jul 11

MP Materials [MP] is down 0.31% over the past day.

Buy
51
NEGG alert for Jul 11

Newegg Commerce [NEGG] is up 74.03% over the past day.

Buy
76
UAL alert for Jul 11

United Airlines Holdings [UAL] is down 4.35% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock